Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 21

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 21
---

Avenue, Suite 204, Newark, Delaware 19711. Our Depositary Shares are traded on the NASDAQ Capital Market under the symbol “BDRX.”

Implications of Being a Foreign Private Issuer

We are incorporated as a public
limited company in England and Wales, are we are deemed to be a “foreign private issuer” for the purposes of the reporting
rules under the Securities Exchange Act of 1934, as amended, or the Exchange Act. In our capacity as a foreign private issuer, we are
exempt from certain rules under the Exchange Act that would otherwise apply if we were a company incorporated in the United States, including:

| · | the requirement to file periodic reports and financial statements with the SEC as frequently or as promptly 
 as United States companies with securities registered under the Exchange Act;                               |

| · | the requirement to file financial statements in accordance with accounting principles generally accepted 
 in the United States, or U.S. GAAP;                                                                      |

| · | the proxy rules, which impose certain disclosure and procedural requirements for proxy solicitations; 
 and                                                                                                   |

| · | the requirement to comply with Regulation FD, which imposes certain restrictions on the selective disclosure 
 of material information.                                                                                     |

In addition, our officers,
directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions of Section
16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our Ordinary Shares. Accordingly,
an investor may receive less information about us that it would receive about a public company incorporated in the United States.

| 10 |

<div align='center'>The Offering</div>

| Issuer                                                                  |     | Biodexa Pharmaceuticals PLC                                                                                                                                                                       |
| Depositary Shares offered by the Selling Shareholder                    |     | Up to 358,750,000,000 Ordinary Shares represented by 35,875,000 Depositary                                                                                                                        
 Shares that have been or may be issued by us to the Selling Shareholder pursuant to the Purchase Agreement, including (i) up to 35,000,000                                                        
 Purchase Shares and (ii) if issued to the Selling Shareholder to release the Company of its liability to pay the Commitment Fee, up to                                                            
 875,000 Commitment Shares. The actual number of Depositary Shares (and the underlying                                                                                                             
 Ordinary Shares) issued and sold pursuant to the Purchase Agreement will vary depending on the then-current market price of our Depositary                                                        
 Shares